iShares Nasdaq Biotechnology ETF (IBB)
104.19
+2.27 +2.23%
NASDAQ
Nov 15, 17:00
Delayed 2m
USD
IBB Key Stats
| Net Asset Value | Upgrade |
| Discount or Premium to NAV | Upgrade |
| Turnover Ratio | Upgrade |
| 1 Year Fund Level Flows | Upgrade |
View All IBB News
IBB News
-
WireHeadlineTime (ET)
-
MT Newswires11/15 13:40
-
MT Newswires11/15 09:27
-
Yahoo11/14 15:09
-
MT Newswires11/14 14:10
-
MT Newswires11/14 09:16
-
MT Newswires11/13 13:28
-
Yahoo11/13 09:40
-
MT Newswires11/13 09:24
-
MT Newswires11/12 13:35
-
MT Newswires11/12 09:23
IBB Performance
| Total Return (Price) | Total Return (NAV) | Cat. Total Return (NAV) | % Rank in Cat. (NAV) | |
|---|---|---|---|---|
| 1M | -8.39% | -8.40% | -4.16% | 85 |
| 3M | -13.02% | -13.04% | -6.68% | 82 |
| 6M | -5.19% | -5.24% | 0.22% | 82 |
| YTD | -4.38% | -4.36% | 5.94% | 85 |
| 1Y | 0.52% | 0.50% | 10.52% | 88 |
| 3Y | -1.65% | -1.65% | 7.09% | 92 |
| 5Y | 8.05% | 8.05% | 11.22% | 78 |
| 10Y | 16.37% | 16.40% | 16.18% | 38 |
| 15Y | 10.77% | 10.76% | 10.91% | 53 |
| 20Y | -- | -- | 10.72% | -- |
IBB Asset Allocation
| Type | % Net | % Long | % Short |
|---|---|---|---|
| Cash | 0.05% | 0.05% | 0.00% |
| Stock | 99.95% | 99.95% | 0.00% |
| Bond | 0.00% | 0.00% | 0.00% |
| Convertible | 0.00% | 0.00% | 0.00% |
| Preferred | 0.00% | 0.00% | 0.00% |
| Other | 0.00% | 0.00% | 0.00% |
IBB Region Exposure
| Americas | 97.85% |
| North America | 97.85% |
| Latin America | 0.00% |
| Greater Europe | 1.77% |
| United Kingdom | 0.59% |
| Europe Developed | 1.18% |
| Europe Emerging | 0.00% |
| Africa/Middle East | 0.00% |
| Greater Asia | 0.38% |
| Japan | 0.00% |
| Australasia | 0.00% |
| Asia Developed | 0.00% |
| Asia Emerging | 0.38% |
| Market Classification | |
| % Developed Markets | 99.62% |
| % Emerging Markets | 0.38% |
IBB Stock Sector Exposure
| Basic Materials | 0.00% |
| Communication Services | 0.00% |
| Consumer Cyclical | 0.00% |
| Consumer Defensive | 0.06% |
| Energy | 0.00% |
| Financial Services | 0.00% |
| Healthcare | 99.92% |
| Industrials | 0.00% |
| Real Estate | 0.00% |
| Technology | 0.02% |
| Utilities | 0.00% |
IBB Stock Market Capitalization
| Giant | 18.00% |
| Large | 35.79% |
| Medium | 26.85% |
| Small | 16.00% |
| Micro | 3.36% |
IBB Stock Style Exposure
| Large Cap Value | 20.96% |
| Large Cap Blend | 8.90% |
| Large Cap Growth | 26.65% |
| Mid Cap Value | 3.11% |
| Mid Cap Blend | 3.18% |
| Mid Cap Growth | 19.98% |
| Small Cap Value | 0.70% |
| Small Cap Blend | 4.02% |
| Small Cap Growth | 12.48% |
View More Holdings
As of Nov. 14, 2018
IBB Top 10 Holdings
| Symbol | Name | % Weight | Price | % Chg |
|---|---|---|---|---|
| AMGN | Amgen Inc | 9.09% | 192.45 | +1.10% |
| GILD | Gilead Sciences Inc | 8.89% | 69.78 | -1.09% |
| BIIB | Biogen Inc | 8.47% | 321.72 | +2.61% |
| CELG | Celgene Corp | 6.74% | 69.98 | +0.50% |
| ILMN | Illumina Inc | 6.24% | 319.51 | +3.66% |
| VRTX | Vertex Pharmaceuticals Inc | 4.26% | 166.67 | +1.27% |
| REGN | Regeneron Pharmaceuticals Inc | 3.96% | 341.65 | +1.29% |
| ALXN | Alexion Pharmaceuticals Inc | 3.73% | 119.68 | +3.07% |
| MYL | Mylan NV | 2.54% | 35.14 | +2.66% |
| BMRN | Biomarin Pharmaceutical Inc | 2.35% | 94.75 | +3.26% |
Advertisement
IBB One Page Reports
- One Page Report Download
IBB Basic Info
| Style | |
|---|---|
| Equity Style | Large Cap/Growth |
| Broad Asset Class | Sector Equity |
| Broad Category | Equity |
| Category Name | Health |
| Prospectus Objective | Specialty - Technology |
| Fund Owner Firm Name | iShares |
| Benchmark Index | |
|---|---|
NASDAQ Biotechnology TR USD |
100.0% |
IBB Manager Info
| Name | Tenure |
|---|---|
| Alan Mason | 2.55 yrs |
| Amy Whitelaw | 0.25 yrs |
| Diane Hsiung | 10.84 yrs |
| Greg Savage | 10.84 yrs |
| Jennifer Hsui | 6.25 yrs |
| Rachel Aguirre | 0.25 yrs |
IBB Net Fund Flows
| 1M | -202.67M |
| 3M | -411.46M |
| 6M | -418.70M |
| YTD | -1.583B |
| 1Y | -1.426B |
| 3Y | 134.23M |
| 5Y | 2.218B |
| 10Y | 2.406B |
IBB Risk Info
| Beta (5Y) | 1.362 |
| Max Drawdown (All) | 62.85% |
| Historical Sharpe (10Y) | 0.8847 |
| Historical Sortino (All) | 0.5462 |
| 30-Day Rolling Volatility | 32.50% |
| Daily Value at Risk (VaR) 1% (All) | 4.84% |
| Monthly Value at Risk (VaR) 1% (All) | 19.32% |
IBB Fundamentals
| Dividend Yield TTM (11-15-18) | 0.30% |
| 30-Day SEC Yield (4-30-18) | 0.13% |
| 7-Day SEC Yield | -- |
| Weighted Average PE Ratio | 27.24 |
| Weighted Average Price to Sales Ratio | 5.486 |
| Weighted Average Price to Book Ratio | 4.654 |
| Weighted Median ROE | 4.51% |
| Weighted Median ROA | -2.57% |
| Forecasted Dividend Yield | 0.65% |
| Forecasted PE Ratio | 14.29 |
| Forecasted Price to Sales Ratio | 4.709 |
| Forecasted Price to Book Ratio | 3.439 |
| Number of Holdings | 193 |
IBB Growth Estimates
| Forecasted 5 Yr Earnings Growth | 14.55% |
| Forecasted Book Value Growth | 13.73% |
| Forecasted Cash Flow Growth | 2.77% |
| Forecasted Earnings Growth | -12.41% |
| Forecasted Revenue Growth | 11.45% |
IBB Attributes
| Key Dates | |
|---|---|
| Inception Date | 2/5/2001 |
| Termination Date | |
| Last Annual Report Date | 3/31/2018 |
| Last Prospectus Date | 8/1/2018 |
| Attributes | |
| Exchange Traded Share | Yes |
| Exchange Traded Note | No |
| Enhanced Index Fund | No |
| Fixed Distribution Fund | No |
| High-Net Worth Individual Fund | No |
| Index Fund | Yes |
| Inverse Fund | No |
| Leveraged Fund | No |
| Fund of Funds | No |
| Currency Hedged Fund | No |
| Synthetic Replication Fund | No |
| Has Dividend Investment Plan | Yes |
| Socially Responsible Fund | No |
| General Availability | |
| Available for Insurance Product | No |
| Available for Retirement Plan | No |
| Available for RRSP | No |
IBB Excel Add-In Codes
- Name: =YCI("IBB","name")
- Broad Asset Class: =YCI("IBB", "broad_asset_class")
- Broad Category: =YCI("IBB", "broad_category_group")
- Prospectus Objective: =YCI("IBB", "prospectus_objective")
To find the codes for any of our financial metrics, see our Complete Reference of Metric Codes.
Access our powerful Excel Add-in with a YCharts Professional Membership. Learn More.
Advertisement
